GlobeNewswireJUN 132 min read$INDP

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

NEW YORK, June 13, 2025 ( GLOBE NEWSWIRE ) -- Indaptus Therapeutics, Inc. ( Nasdaq: INDP ) ( "Indaptus" ) , a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate ...

Original reporting

GlobeNewswire · Indaptus Therapeutics

Published Jun 13, 2025, 12:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 13, 2025, 1:00 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants — source image — Source · www.globenewswire.com

Decision brief

The 30-second read

$INDPNeutralLow

Why it matters

The private placement indicates ongoing capital raising efforts, which may support future development but also introduce dilution concerns.

Market read

The news has limited immediate trading impact but is relevant for assessing the company's financial health and potential future dilution.

What to watch

Market conditions and investor appetite for biotech funding could influence the stock's response; broader industry trends should be considered.

Timing: short-term (next few days)

Background

Indaptus Therapeutics is a clinical-stage biotech company focusing on cancer and viral infection treatments.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$INDPNeutralMedium confidence

Context

The news pertains directly to Indaptus Therapeutics, Inc., a biotech company involved in clinical-stage treatments.

Expected impact

Minimal immediate impact; potential for slight positive movement if the market perceives fundraising as confidence-building.

Evidence & confidence

The news is primarily financial and does not directly affect the company's operational outlook or product pipeline. The relevance score is moderate due to the company's biotech focus and the financial nature of the news.

Market effects

Sector

Potential slight positive influence on biotech sector due to fundraising activity.

Regional

Limited; primarily affecting US markets where the company is listed.

Global

Negligible; the news is company-specific and financial in nature.

Counterpoint

What could challenge this read

The fundraising could signal financial weakness or need for capital, which might be viewed negatively by investors.

Key entities

Company
Indaptus Therapeutics, Inc.
A biotech firm developing treatments for cancer and viral infections.

Read at source ← All news

AUG 13

$INDPMed

Indaptus Therapeutics, Inc. (INDP): Results of Operations and Financial Condition

Indaptus Therapeutics, Inc. (INDP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK (August 13, 2026) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a biotechnology company dedicated to

SEC EDGAR 8-K4 min

AUG 13

$INDPMedAI 8/10

Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Indaptus Therapeutics (Nasdaq: INDP) reported Q2 2026 results and a corporate update. It raised about $12.0 million via a June 17 private placement at $0.60 per share. The company discontinued further Decoy20 enrollment and has no active clinical programs. Q2 R&D fell to ~$0.4M and net loss to ~$1.8M. Cash and short-term investments were ~$11.6M at June 30.

finanznachrichten.de4 min

JUN 18

$QUREMedAI 8/10

Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch

uniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.

rttnews.com5 min

AUG 24

$JNJMedAI 8/10

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Johnson & Johnson (JNJ) proposed a $5.5B settlement for 76,000 talc-related lawsuits, but it requires 95% claimant approval and may exceed this amount. The company has $21B in cash and expects to pay $3B in 2027, with further payments starting in 2028. A judge's recent ruling may strengthen JNJ's legal position. Investors weigh the benefit of reduced uncertainty against potential higher costs.

yahoo.com2 min

AUG 23

$CRWDMed

Analysts Back CrowdStrike, Dell and SanDisk Growth

Wall Street analysts maintain positive outlooks on CrowdStrike, Dell, and SanDisk, citing long-term growth in cybersecurity, AI infrastructure, and storage. CrowdStrike's price target raised to $245 by Truist, Dell's to $550 by Evercore, and SanDisk's to $2,250 by J.P. Morgan, all with buy ratings.

ozarab.media2 min